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The B-amyloid peptide (4s) is a 4 kDa proteolytic fragment derived from the &unyloid precursor protein @APP) which is deposited as amyloid 
fibrils in the brains of patients with Alzheimer’s disease. BAPP processing was investigated in C6 glioma cells using several affinity-purified 
anti-peptide antibodies raised against different domains of the protein. Both direct immunoblot analysis of C6 glioma conditioned medium and 
metabolic labeling of cells followed by immunoprecipitation of extracellular medium with specific antibodies revealed that these glial cells normally 
produce and release a soluble 4 kDa peptide which co-migrates with synthetic @ (l-40) and is specifically recognized by antibodies raised against 
N- or C-terminal domains of the /?-amyloid peptide. Our results further suggest hat glial cells may prove a major source of B-amyloid production 
in the nervous tissue. 
Alzheimer’s disease; /?-Amyloid peptide; Glial cell 
1. INTRODUCTION 
The major neuropathological characteristic of Alz- 
heimer’s disease is the progressive deposition in the 
brain and its microvasculature of insoluble aggregates 
of/&unyloid peptide (AB) [l-3]. This hydrophobic pep- 
tide of 3943 residues (- 4 kDa) is a small fragment con- 
tained within a larger membrane-spanning lycopro- 
tein, the /?-amyloid precursor protein (BAPP), which is 
expressed in most mammalian cells as a combination of 
different isoforms (mainly /?APP 695, 751 and 770) de- 
rived by alternative splicing [2,4,5]. The /I-amyloid pep- 
tide includes 28 residues just outside the membrane plus 
the first 11-15 residues of the putative transmembrane 
domain of/3APP The understanding of the intracellular 
processing of /3APP and of the pathways leading to A/I 
generation are essential issues in research on Alzheimer 
disease. 
Moreover, very recent reports have put forward the 
unexpected finding that a soluble form of the 4 kDa A/? 
peptide is produced normally by cultured cells and is 
present in cerebrospinal fluid [2,13-161. Initial studies 
have suggested that the characteristics and extent of qS 
production are dependent on cell type [16]. In this re- 
gard, very little is known aboutbAPP processing in glial 
cells, despite the fact that substantial expression of the 
protein has been reported in astrocytes, microglia and 
C6 glioma cells [17-201. In this report, we show, using 
several aflinity-purified anti-peptide antibodies raised 
in our laboratory against different domains of A/I and 
BAPP, that active generation and secretion of the 4 kDa 
A/? peptide takes place in C6 rat glioma cells. 
2. MATERIALS AND METHODS 
2.1. Antibodies 
The /3APP can be processed through a constitutive 
secretory, non-amyloidogenic pathway, which involves 
its cleavage by an endoproteinase (a-secretase) at posi- 
tion 16 within A/?, releasing a large soluble /JAPP ecto- 
domain and retaining in the plasma membrane a C- 
terminal fragment of- 10 kDa [6,7]. Alternatively,/?APP 
molecules can be targetted to the endosomaYlysosoma1 
system (probably by re-internalization from the cell sur- 
face), where they give rise to a variety of potentially 
amyloidogenic C-terminal fragments, which are further 
degraded in an acidic intracellular compartment [S-12]. 
Antibodies AB74, AB597a, AB597b and Ab597c were generated 
against synthetic peptides (obtained from Biosynthesis Inc. and Dr. 
M. Patarroyo) corresponding to residues 7487,597-612,61&625 and 
625638, respectively, of human /?APP (numbering is according to 
BAPP 695, see [4]). The localization of the antigenic peptides inBAPP 
is depicted in Fig. 1. For afhnity purification, the corresponding pep- 
tides were covalently coupled to Affigel-10 or Affigel 102 columns 
(Bio-Rad) according to the protocol of the manufacturer, and anti- 
bodies purified as described [21]. When tested by immunoblotting, 
these purified antibodies recognized maturepAPP in C6 glioma condi- 
tioned medium and cell lysates, and such reactivity was blocked by 
preabsorption with the corresponding peptide antigens (Morato and 
Mayor, to be described elsewhere). 
2.2. Cell culture 
*Corresponding author. Fax: (34) (1) 397 4799. 
Abbreviofions: A/& &unyloid peptide; BAPP, B-amyloid precursor 
protein; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel elec- 
trophoresis. 
Rat C6 glioma cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 2.5% fetal calf serum, 10% 
horse serum and 1% glutamine. When required, 10 ml aliquots of 
medium were conditioned in the presence of 20 x lo6 cells per PlOO 
dish for 12 h, either in the presence or absence of serum. After this time 
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the medium was removed, cleared of debris by centrifugation at 
1,000 x g for 10 min, and concentrated five-fold by lyophylization, 
prior to analysis by gel electrophoresis and immunoblotting. Total cell 
lysates (in 50 mM Tris-HCl, pH 7.5, 2% SDS, 150 mM NaCI, 2 mM 
phenylmethylsulfonylfluoride, 1 mM benzamidine, 1&ml leupeptin, 
0.1 ,&ml pepstatin) were also investigated in the same way. In some 
experiments, conditioned medium was centrifuged at 100,000 x g for 
90 min (Beckman TL-100) and the supematant processed as above, 
or immunoprecipitated with antibody AB597a, as described below. 
2.3. Metabolic labeling and immunoprecipitation 
C6 glioma cells were grown to about 90% confluence in lo-cm 
dishes. After removal of culture medium, cells were incubated for 
2 h in methionine-free medium, and then labeled for 12 h in the same 
volume with 1 mCi of 35S Protein labeling Mix (New England Nu- 
clear, Boston), either in the absence or presence of serum. For im- 
munoprecipitation, the medium was made lx in RIPA-LPT buffer 
(150 mM NaCl, 10 mM Tris-HCI, pH 8, 1% Nonidet P-40,0.5% cholic 
acid, 0.1% SDS, 5 mM EDTA, 1 &ml leupeptin, 0.1 &ml pepstatin, 
2 mM phenylmethylsulfonylfluoride). The affinity-purified antibody 
AB597a (1:250) and 50 ~1 of protein A-agarose slurry washed in 
RIPA-LPT were then added and the mixture incubated at 4°C for 
12 h [6]. After washing the agarose beads 34 times with RIPA-LPT, 
the immunoprecipitated proteins were resuspended in reducing SDS 
sample buffer and analyzed by Tris-Tricine SDS-PAGE on a 16.5% 
gel [13]. The gel was fixed in acetic acid:ethanol (10:50), incubated in 
Amplify (Amersham) and labeled proteins visualized by autoradiogra- 
phy. 
2.4. Gel electrophoresis and immunoblotting 
Conditioned medium, total cell lysates or immunoprecipitates were 
resolved by 16.5% Tris-Tricine SDS-PAGE for improved detection of 
low molecular weight fragments [22] and electroblotted to Immobilon 
filters (Millipore). Membranes were blocked in TBS-BSA (10 mM 
Tris-HCl, pH 7.5, 150 mM NaCI, 5% bovine serum albumin) followed 
by incubation with the desired purified antibody (1:3,000 in TBS-BSA) 
for 12 h at 4°C. Filters were washed (3 x 15 min) in TBS containing 
0.1% Tween 20 and developed using a chemiluminiscence method 
(ECL, Amersham Corp.) after incubation with a goat anti-rabbit 
antibody conjugated to peroxidase. For peptide pre-absorption con- 
trols, the antibody was pre-incubated with 100 pg/ml of the peptide 
immunogen for 12 h at 4°C. 
3. RESULTS AND DISCUSSION 
The possible production and secretion of low molecu- 
lar weight BAPP derivatives by C6 glioma cells was 
initially investigated by resolving the conditioned me- 
dium by 16.5% Tris-Tricine SDS-PAGE followed by 
APP 
immunoblot analysis using antibodies raised against 
different domains of A/I and BAPP (see scheme in 
Fig. 1). Fig. 2A shows that a secreted peptide of m 4 kDa 
is recognized by antibodies raised against the N-termi- 
nus (AB597a, lane 2), the middle region (AB597b, lane 
3), and the C-terminus (Ab597c, lane 4) of the j?-amy- 
loid peptide, whereas this band is not immunoreactive 
with an antibody to the N-terminal domain of BAPP 
(AB74, lane 1). When the conditioned medium is im- 
munoprecipitated with the antibody raised against the 
N-terminus of A/?, a 4 kDa protein can be immunola- 
beled by both AB597a and AB597c (Fig. 2B, lanes 1 and 
3, respectively). Pre-absorption of these antibodies with 
their corresponding synthetic peptide immunogens 
abolished reactivity with the 4 kDa peptide (Fig. 2B, 
lanes 2 and 4). Thus, two different experimental ap- 
proaches indicate that the 4 kDa protein detected in C6 
glioma cells conditioned medium contains both the N- 
and C-terminal domains of the p-amyloid peptide. 
Fig. 3A shows that non-conditioned medium does not 
display the 4 kDa protein recognized by the AB597a 
antibody (lane l), thus ruling out the possibility of a 
non-cellular origin of this peptide (see also the experi- 
ment depicted in Fig. 3B). Fig. 3A also indicates that the 
4 kDa protein present in the C6 glioma extracellular 
medium (lane 3) co-migrates with synthetic A/3 (140) 
peptide resolved in the same gel and labeled with the 
same AB597a antibody (lane 2) thus further suggesting 
that the 4 kDa peptide corresponds to the B-amyloid 
peptide fragment of /3APP. This fragment appears to be 
released from C6 glioma cells in a soluble form, since 
when cell-conditioned medium was centrifuged at 
100,000 x g for 90 min and analyzed by immunoblotting 
with the AB597a antibody, the 4 kDa protein was found 
in the supernatant (Fig. 3A, lane 4). To further demon- 
strate that the A/? peptide was produced and secreted by 
these glial cells, we metabolically labeled C6 glioma 
cultures with [35S]methionine for 12 h. Immunoprecipi- 
tation of the conditioned medium with AB597a fol- 
lowed by electrophoresis and autoradiography revealed 
a 4 kDa band (Fig. 3B) which was absent in im- 
munoprecipitations with pre-absorbed serum (data not 
- Proposed sites of proteasc cleavage 
m p-anyloid pcptide I I PM 
Fig. 1. Schematic representation of the localization of the synthetic peptide antigens within the structure of the /?-amyloid precursor protein. AB74 
was generated against he N-terminus of BAPP, whereas AB597a, AB597b and AB597c were raised against domains a, b and c of the B-amyloid 
peptide, respectively. PM, plasma membrane. 
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Fig. 2. C6 glioma cells release to the extracellular medium a 4 kDa peptide which is specifically detected by antibodies raised against different 
domains of the /I-amyloid peptide. (A) 25 ,~l aliquots of concentrated C6 glioma cells conditioned medium were resolved by 16.5% Tris-Tricine 
SDS-PAGE, transferred to Immobilon membranes and immunoblotted as detailed in section 2 with the affinity-purilied antibodies AB597a (lane 
2), AB597b (lane 3) and AB597c (lane 4) raised against different domains of w (see Fig. 1), or AB74 (lane 1) raised against an N-terminal domain 
ofjIAPP. (B) The 4 kDa peptide is immunoprecipitated from C6 glioma cells conditioned medium. Extracellular medium proteins were immunopre- 
cipitated with the affinity-purified antibody, AB597a, as detailed in section 2 resolved by Tris-Tricine SDS-PAGE and immunoblotted as in A with 
AB597a (lanes 1 and 2) or AB597c (lanes 3 and 4) without (lanes 1 and 3) or with (lanes 2 and 4) previous pre-absorption with the specific 
immunogens. The migration of low M, standards (Pharmacia-LKB) is shown on the left in both panels and the position of the 4 kDa peptide is 
marked by an arrow. 
shown). Similar amounts of the labeled peptide were 
detected when the labeling was performed in the pres- 
ence (lane 1) or absence (lane 2) of serum. 
In conclusion, several ines of evidence indicate that 
C6 glioma cells secrete to the medium a soluble 4 kDa 
peptide which co-migates with synthetic 48 (l-40) and 
contains its N- and C-terminal domains, as indicated by 
immunoreactivity with antibodies raised against these 
regions of qS. Our results are consistent with recent 
reports showing that A,8 is a normal secretory product 
of different cell types [13-161. The production of /3- 
amyloid peptide by glial cells is of particular physiolog- 
ical relevance, given their abundant presence in the 
nervous tissue. During the preparation of this work, 
Busciglio et al. [16] have also found that primary cul- 
tures of human and rat astrocytes generate high levels 
of the 4 kDa /?-amyloid peptide relative to other cell 
types in their study, including neurons. In line with this 
report, our data further suggest hat glial cells may be 
a major source of B-amyloid in the brain. The exact site 
of production of w within the cells has not been iden- 
tified to date. Although very recent reports suggest he 
involvement of endosomes/lysosomes or other acidic 
components in the initial production and further degra- 
dation of potentially amyloidogenic BAPP C-terminal 
fragments [12], the presence of the 4 kDa peptide has 
not been reported in lysates from/3APP_transfected cells 
secreting /?-amyloid [2,13,14,23]. The higher levels of 
production of A/? in glial cells may explain preliminary 
results in our laboratory which indicate the presence of 
the /I-amyloid peptide in cell lysates (Morato and 
Mayor, in preparation), although more detailed subcel- 
lular localization studies need to be performed. 
A 
B 
Fig. 3. Characterization of the 4 kDa peptide produced and secreted 
by C6 glioma cells. (A) The 4 kDa peptide is released in a soluble form 
and co-migrates with synthetic /I-amyloid peptide. Non-conditioned 
cell culture medium (lane l), synthetic A/l (l-40) (lane 2), or C6 glioma 
cells conditioned medium before (lane 3) and after (lane 4) centrifuga- 
tion at 100,000 x g for 90 min were resolved by SDS-PAGE, trans- 
ferred to membranes and immunoblotted with AB597a, as in Fig. 2A. 
(B) Immunoprecipitation of labeled 4 kDa peptide from the extracellu- 
lar medium. C6 glioma cells were metabolically labeled with 
[‘5S]methionine for 12 h in the presence (lane 1) or absence (lane 2) of 
serum, and 2 ml aliquots of the conditioned medium immunoprecipi- 
tated with AB597a, as detailed in section 2, followed by 16.5% Tris- 
Tricine SDS-PAGE and autoradiography. The migration of low M, 
standards (Pharmacia-LKB) is shown to the left and the position of 
the 4 kDa peptide is marked by an arrow. 
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It is worth noting that, under our experimental condi- 
tions, C6 glioma cells do not release a truncated 3 kDa 
/3-amyloid peptide that has been detected in the extracel- 
lular medium of /3APP-transfected cells, cultured rat 
neurons and neuroblastoma or pheochromocytoma cell 
lines [13,15,16,23]. This truncated form lacks the N- 
terminal portion of A@ and seems to be derived from the 
- 10 kDa C-terminal fragment of BAPP which remains 
in the plasma membrane after a-secretase cleavage, thus 
acting as a marker for the activity of the secretory, 
non-amyloidogenic pathway [2,23]. Our experimental 
finding is consistent with previous reports indicating 
low levels of such constitutive/IAPP cleavage and secre- 
tion in microglia and astrocytes [19], and with the very 
low levels of the 3 kDa peptide compared to the full- 
length A/3 recently reported in astrocytes-conditioned 
medium [16]. Thus, there may be significant variations 
in the cellular processing of BAPPP in different cell 
types, such as neurons and glia. Given the important 
trophic interactions between neurons and glia, and the 
reported association of activated astrocytes and micro- 
glia with senile plaques found in Alzheimer’s disease 
[2,24,25], the investigation of BAPP processing in glial 
cells may prove essential for understanding the forma- 
tion and development of amyloid deposits. The availa- 
bility of a well-known cell system model, such as C6 rat 
glioma, that exhibits A/? generation should allow a de- 
tailed study of the regulation of the cellular pathways 
leading to the formation of j?-amyloid peptide in glial 
cells. 
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